合并症对T3/T4喉癌治疗方案及生存的影响
基于美国国家癌症数据库(NCDB)纳入14,053例T3/T4喉癌患者的回顾性研究,采用Charlson-Deyo合并症指数(CDCI)评估合并症负荷。随着CDCI升高,患者更少接受全喉切除术或放化疗(CRT)(P<0.0001),CDCI≥1者较CDCI 0者更可能接受全喉切除术(P<0.0001)。T3期肿瘤中CRT与全喉切除术的总生存(OS)无差异;T4期肿瘤中除CDCI≥3外,全喉切除术与CRT相比均与OS改善相关。
要点
- CDCI升高与偏离全喉切除术或CRT的治疗选择相关(P<0.0001)
- T3期喉癌中CRT与全喉切除术的OS无差异
- T4期喉癌中除CDCI≥3外全喉切除术与OS改善相关
核心结论
- 结果支持现行国家指南:T3期推荐CRT或全喉切除术,T4期优先全喉切除术,且该结论在CDCI评分增加的患者中总体一致。
研究设计与样本
- 回顾性分析美国国家癌症数据库(NCDB)中T3和T4期喉癌患者,共纳入14,053例,以Charlson-Deyo合并症指数(CDCI)计算合并症评分。
主要发现
- 65%患者CDCI评分为0,25%、7%、3%分别为1、2、≥3。
- 随着CDCI升高,患者更可能接受全喉切除术或CRT以外的治疗选项(P<0.0001)。
- CDCI≥1的患者较CDCI 0者更可能接受全喉切除术(P<0.0001)。
- T3期肿瘤中,任何CDCI评分下CRT与全喉切除术的OS无差异。
- T4期肿瘤中,除CDCI≥3外,全喉切除术与CRT相比在所有CDCI评分下均与OS改善相关。
关键数值与推荐
- T3期喉癌:推荐CRT或全喉切除术。
- T4期喉癌:优先推荐全喉切除术。
- 上述推荐在CDCI评分增加的患者中总体一致。
临床怎么用
- 临床可根据CDCI评估合并症负荷,辅助T3/T4喉癌的治疗决策。
- T3期可考虑CRT或全喉切除术,T4期优先考虑全喉切除术,但CDCI≥3时需个体化评估。
局限性
- 本研究为基于NCDB的回顾性分析,证据级别为NA(Laryngoscope, 130:1459-1464, 2020)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Investigate the impact of medical comorbidities on treatment regimen and overall survival (OS) in patients with locally advanced laryngeal cancer. STUDY DESIGN: Retrospective Review of the National Cancer Database (NCDB). METHODS: The NCDB was queried for patients with T3 and T4 laryngeal cancer. Comorbidity scores were calculated from the Charlson-Deyo comorbidity index (CDCI). Univariate and multivariate analyses explored the association of CDCI scores on treatment regimen and OS. RESULTS: 14,053 patients were analyzed. 65% of patients had a CDCI score of 0, whereas 25%, 7%, and 3% had CDCI score of 1, 2, and ≥3, respectively. As patients' CDCI increased, they became more likely to receive treatment options other than a laryngectomy or chemoradiation therapy (CRT) (P < 0.0001). Patients with CDCI ≥1 were more likely have a laryngectomy than those with CDCI 0 (P < 0.0001). In patients with T3 tumors, OS did not differ between those receiving CRT versus laryngectomy with any CDCI score. In patients with T4 tumors, laryngectomy was associated with improved OS compared to CRT across all CDCI scores except CDCI ≥3. CONCLUSION: Our results support the current national guidelines with a recommendation for CRT or TL for T3 tumors and a preference for TL for T4 tumors. These outcomes are generally consistent in patients as their CDCI scores increases. LEVEL OF EVIDENCE: NA Laryngoscope, 130:1459-1464, 2020.
引用
- Bollig C, Ahmad J, Dooley L, et al. Effect of medical comorbidities on treatment regimen and survival in T3/T4 laryngeal cancer. Laryngoscope. 2019. PMID: 31408205. doi:10.1002/lary.28227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。